3xTg-AD mice treated with aCSF showed remarkably elevated levels of phosphorylated tau (T181, T205, and T231) and tau compared with aCSF-infused wild type mice, whereas GQ1b-treated 3xTg-AD mice had significantly lower levels of phosphorylated tau, but not tau in the hippocampus (Fig. 5A,B). This evidence concerns the gene MAPT and Alzheimer disease.